TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25841041
Drug: Aripiprazole 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 1.4 mg/d
Study: 25841041
Drug: Asenapine 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 0.9 mg/d
Study: 25841041
Drug: Chlorpromazine 38.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine 38.9 mg/d
Study: 25841041
Drug: Clozapine 30.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 30.6 mg/d
Study: 25841041
Drug: Haloperidol 0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 0.7 mg/d
Study: 25841041
Drug: Quetiapine 32.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 32.3 mg/d
Study: 25841041
Drug: Risperidone 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 0.4 mg/d
Study: 25841041
Drug: Sertindole 1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole 1.1 mg/d
Study: 25841041
Drug: Ziprasidone 7.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 7.9 mg/d
Study: 25841041
Drug: Zotepine 13.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zotepine 13.2 mg/d
Study: 24067385
Drug: Subcutaneous white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous white adipose tissue (SWAT) biopsies pre-intervention
Study: 24067385
Drug: Subcutaneous white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous white adipose tissue (SWAT) biopsies post-intervention
Study: 19226352
Drug: Dairy intervention
Normalized name: Beano Dairy Defense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy intervention group (IG: n = 39) receiving approximately 1200 mg of calcium and 7.5 microg of vitamin D(3) per day via fortified dairy products and attending biweekly nutrition counselling sessions
Study: 19226352
Drug: Calcium-supplemented group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-supplemented group (SG: n = 26) receiving a total of 1200 mg calcium per day
Study: 8222489
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg cefdinir alone
Study: 8222489
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg cefdinir with two tablets of iron ion concomitantly
Study: 8222489
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg cefdinir with two tablets of iron ion preparation 3 hours later
Study: 3978009
Drug: Weight-related dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-related dose of buprenorphine, age, sex, body weight, duration of anaesthesia, dose of droperidol or thiopentone
Study: 30853329
Drug: Vibration and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration and cold gel pack application
Study: 25820842
Drug: Ayahuasca (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayahuasca (a psychedelic preparation containing N,N-dimethyltryptamine)
Study: 21172601
Drug: Statistically significant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statistically significant results for efficacy, private funding, primary harms outcome, and anti-infective, antineoplasmatic, or immunosuppressive agents
Study: 11795467
Drug: Heat treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat treatment of whole blood in vitro for 2 hours at different temperatures (up to 41 degrees C)
Study: 7846203
Drug: Flumazenil (1
Normalized name: Flumazenil (18-F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (1 mg IV)
Study: 30051155
Drug: Attention Control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention Control Condition (CC)
Study: 28342090
Drug: Standard patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard patch
Study: 25277390
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (210 IU and 420 IU)
Study: 25277390
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of ins‐asp (0.12 IU/kg/24 h)
Study: 23620931
Drug: Balance needling
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance needling therapy
Study: 21148517
Drug: Telavancin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telavancin (10 mg/kg every 24 h)
Study: 18093662
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) 300-800 mg/daily (mean final dose 461.6 mg/day)
Study: 12898007
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg orally twice daily for 4 days
Study: 10725065
Drug: Neoral (microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral (microemulsion formulation of cyclosporin A)
Study: 10725065
Drug: Sandimmun (original
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandimmun (original formulation of cyclosporin A)
Study: 2438997
Drug: Novel oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel oral rehydration mixture based on fruit juice cordial
Study: 29626933
Drug: Nutrition Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition Therapy with RDN to develop an individualized eating plan (Group A)
Study: 29626933
Drug: Nutrition Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition Therapy with RDN and a structured meal plan (Group B)
Study: 29626933
Drug: Nutrition Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition Therapy with RDN, a structured meal plan, and weekly phone support (Group C)
Study: 18312763
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg and Fenofibrate 160 mg (Combination therapy)
Study: 16768549
Drug: Polychromatic light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polychromatic light (480-3400 nm) at a therapeutic dose of 12 J/cm²
Study: 11149164
Drug: Photocoagulation laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photocoagulation laser therapy
Study: 11149164
Drug: Prompt diagnosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt diagnosis and treatment for endophthalmitis and mucormycosis
Study: 11149164
Drug: Emergent ophthalmologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergent ophthalmologic evaluation and treatment for herpes zoster infection
Study: 8731519
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg DMT fumarate
Study: 19577308
Drug: SRI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRI treatment (clomipramine, fluvoxamine, or fluoxetine)
Study: 9010690
Drug: ketoprofen 3
Normalized name: ketoprofen 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoprofen 3 x 25 mg per day
Study: 9010690
Drug: ketoprofen 3
Normalized name: ketoprofen 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoprofen 3 x 50 mg per day
Study: 9010690
Drug: ibuprofen 3
Normalized name: ibuprofen 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen 3 x 200 mg per day
Study: 9010690
Drug: ibuprofen 3
Normalized name: ibuprofen 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen 3 x 400 mg per day
Study: 1504643
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (50 micrograms/70 kg)
Study: 6421508
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) 2 g/l
Study: 6421508
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) 20 g/l
Study: 6421508
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) 40 g/l
Study: 31443961
Drug: Adjuvant docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant docetaxel 75 mg/m2 every 3 weeks for 6 cycles (arm A)
Study: 18928633
Drug: Glucocorticoid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid treatment (n = 35)
Study: 18928633
Drug: Anti-HP treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-HP treatment (n = 30)
Study: 18928633
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (glucocorticoid + HP eradication, n = 35)
Study: 10512960
Drug: Implant-supported overdenture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported overdenture (IOD)
Study: 7796075
Drug: Dietary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary therapy
Study: 28495389
Drug: Antibiotics scenario
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics scenario
Study: 28495389
Drug: Vaccine-hesitancy scenario
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-hesitancy scenario
Study: 15185877
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug (ranitidine, 150 mg b.d.)
Study: 9701194
Drug: Short-chain fructans
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-chain fructans (10-30 g)
Study: 9701194
Drug: Long-chain fructans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-chain fructans (10-30 g)
Study: 7977881
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate reduced-dose group (average 11.5 mg every 2 weeks)
Study: 7977881
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate control group (23 mg every 2 weeks)
Study: 1071665
Drug: Phentolamine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine administration
Study: 27552500
Drug: Indomethacin 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 0.1% 3 times daily for 1 week
Study: 27552500
Drug: Dexamethasone 0.1%
Normalized name: DEXAMETHASONE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.1% 3 times daily for 1 week
Study: 27552500
Drug: No anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-inflammatory treatment
Study: 22123802
Drug: Antibiotics (omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (omeprazole, amoxicillin trihydrate, and clarithromycin) for 10 days
Study: 15257176
Drug: rilmenidine 1
Normalized name: rilmenidine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilmenidine 1 mg twice daily
Study: 7997386
Drug: Intravenous fructose‐1,6‐diphosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fructose‐1,6‐diphosphate 125 mg/kg
Study: 7997386
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 1.3 ml/kg
Study: 20087376
Drug: Multivitamins and
Normalized name: multivitamins and iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamins and 7 mg Zinc daily for 10 weeks
Study: 18174214
Drug: Dexamethasone (Dex:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (Dex: 2 x 2 mg per day)
Study: 10326325
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate tablets containing 60 mg of elemental iron
Study: 10326325
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate tablets containing 120 mg of elemental iron
Study: 10326325
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate tablets containing 180 mg of elemental iron
Study: 10326325
Drug: Ferrous fumarate
Normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous fumarate syrup
Study: 10326325
Drug: Gelatin capsules
Normalized name: Gelatin Capsules
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsules containing pure ferrous salt
Study: 10326325
Drug: Ferrous fumarate
Normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous fumarate tablets
Study: 10326325
Drug: Powdered ferrous
Normalized name: ferrous sulfate Topical Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered ferrous sulphate tablets
Study: 10326325
Drug: Iron tablets
Normalized name: Iron 65 MG Oral Tablet [LEADER IRON TABLETS]
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron tablets distributed by the NNAPP
Study: 8622045
Drug: Third-generation chemotherapy
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-generation chemotherapy regimens (F-MACHOP or MACOP-B)
Study: 1933116
Drug: Textured surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Textured surface silicone implants
Study: 1933116
Drug: Smooth surface
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smooth surface silicone implants
Study: 7310012
Drug: Lodoxamide tromethamine
Normalized name: Lodoxamide Tromethamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lodoxamide tromethamine (0.1 mg in saline)
Study: 30192638
Drug: Mepolizumab (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (750 mg intravenously)
Study: 28064380
Drug: Admission albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Admission albumin < 30 g/L
Study: 19335534
Drug: Sulfonylurea (SU)
Normalized name: sulfanilylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea (SU) or combination of SU/metformin (Met)/thiazolidinediones (TZD)
Study: 19335534
Drug: Metformin (Met)/Thiazolidinediones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (Met)/Thiazolidinediones (TZD)
Study: 17991260
Drug: Rectal diclofenac
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diclofenac 1 mg.kg(‐1)
Study: 17991260
Drug: Paracetamol 40
Normalized name: Hydrocodone bitartrate 5 mg and paracetamol 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 40 mg.kg(‐1)
Study: 17991260
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rectal diclofenac and paracetamol
Study: 9481597
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg sibutramine
Study: 9481597
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg sibutramine
Study: 9481597
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg and 15 mg sibutramine
Study: 2515494
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc acetate (6-month study)
Study: 2515494
Drug: Oral pergolide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pergolide mesylate (3-month crossover study)
Study: 31735650
Drug: We Immunize
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: We Immunize program (2-hour enhanced training and tailored monthly feedback for 6 months)
Study: 18813910
Drug: Respiratory physiotherapy
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory physiotherapy (six treatments: positioning, manual hyperinflation, and suctioning in each 24-hour period while on mechanical ventilation)
Study: 17503315
Drug: Octreotide 30
Normalized name: octreotide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 30 mg monthly alone
Study: 17503315
Drug: Octreotide 30
Normalized name: octreotide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 30 mg monthly in combination with rofecoxib (up to 50 mg bid daily)
Study: 15066461
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day of CEE and calcium
Study: 11806623
Drug: roxithromycin tablets
Normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin tablets 300 mg once a day (Rx)
Study: 11806623
Drug: amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin/clavulanic acid tablets 875+125 mg twice a day (Acx)
Study: 25931293
Drug: Needle aspiration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle aspiration and antibiotics
Study: 17312647
Drug: Injection sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection sclerotherapy (IS)
Study: 30974049
Drug: Pooled data
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled data of Revefenacin 88 μg and 175 μg
Study: 25523285
Drug: antipsychotics
Normalized name: ANTIPSYCHOTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: antipsychotics
Study: 24790178
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg) plus ezetimibe (10 mg) daily
Study: 22534815
Drug: Bortezomib 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.8 mg/m weekly on day 1 and day 8, carboplatin AUC 6, and bevacizumab 15 mg/kg every 3 weeks.
Study: 22534815
Drug: Bortezomib 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.8 mg/m weekly on day 1 and day 8, carboplatin AUC 6, and bevacizumab 15 mg/kg every 3 weeks (phase II portion).
Study: 22534815
Drug: Treatment related
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment related grade-3/4 toxicities.
Study: 17179250
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine (TDS) 1.5 mg
Study: 17179250
Drug: Droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1.25 mg IV
Study: 15049459
Drug: DEC 6
Normalized name: Zodryl DEC 60 Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC 6 mg/kg + ALB placebo
Study: 11493282
Drug: Reviparin at
Normalized name: reviparin
DrugBank: Reviparin (DB09259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reviparin at a dose of 85 IU anti‐Xa/kg
Study: 11493282
Drug: Nadroparin at
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin at a standard dose of 70 IU anti‐Xa/kg
Study: 9489907
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole and 150 mg TAP
Study: 24188203
Drug: Nebulized high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized high-dose budesonide (BUD group)
Study: 17113722
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate (NaP)
Study: 21979395
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate (NaP) plus alverine citrate
Study: 18466681
Drug: T-614 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-614 25 mg daily
Study: 18466681
Drug: T-614 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-614 50 mg daily
Study: 2938923
Drug: Floxuridine infusions
Normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Floxuridine infusions into the hepatic artery using a totally implantable pump system (Infusaid, model 400)
Study: 31735618
Drug: Flibanserin 100
Normalized name: flibanserin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 100 mg + ethanol 0.6 g/kg
Study: 31735618
Drug: Flibanserin 100
Normalized name: flibanserin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 100 mg + ethanol 0.4 g/kg
Study: 31735618
Drug: Flibanserin 100
Normalized name: flibanserin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 100 mg + ethanol 0.2 g/kg
Study: 31735618
Drug: Flibanserin 100
Normalized name: flibanserin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 100 mg only
Study: 31735618
Drug: Flibanserin 100
Normalized name: flibanserin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 100 mg with ethanol (0.2-0.6 g/kg)
Study: 31735618
Drug: Flibanserin 100
Normalized name: flibanserin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 100 mg + ethanol (0.4 g/kg and 0.6 g/kg)
Study: 31735618
Drug: Flibanserin 100
Normalized name: flibanserin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 100 mg + ethanol
Study: 1709335
Drug: Chomelanum (preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chomelanum (preparation A)
Study: 1709335
Drug: Lasonil (preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasonil (preparation B)
Study: 1709335
Drug: Ointment base
Normalized name: Ointment base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment base of Chomelanum (preparation C)
Study: 22258291
Drug: Inhaled sevoflurane
Normalized name: sevoflurane Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled sevoflurane
Study: 20708349
Drug: Regular prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular prescription of BZD
Study: 12814272
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment (ST) plus Motivational Interviewing
Study: 6155131
Drug: Pseudoephedrine 120
Normalized name: CTM 8/PSEUDOEPHEDRINE 120MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine 120 mg
Study: 1804647
Drug: Terfenadine-pseudoephedrine combination
Normalized name: pseudoephedrine / terfenadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine-pseudoephedrine combination
Study: 6391829
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg meptazinol 4-times daily
Study: 6391829
Drug: 65 mg
Normalized name: opium 65 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 65 mg dextropropoxyphene plus 650 mg paracetamol 4-times daily
Study: 26085822
Drug: N-3 supplementation
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-3 supplementation (5 ml seal oil, 375 mg EPA, 230 mg DPA, 510 mg DHA)
Study: 26085822
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 ml olive oil)